vesiculobullous skin disease: Skin diseases characterized by local or general distributions of vesicles and bullae (i.e. blisters). Both vesicles and bullae are fluid-filled lesions, distinguished by size (vesicles being less than 5–10 mm and bullae being larger than 5–10 mm). Vesiculobullous diseases are classified according to the site and mode of blister formation. Lesions can appear spontaneously or be precipitated by infection, trauma, or sunlight. Etiologies include immunologic and genetic factors. In the case of vesiculobullous diseases which are also immune disorders, the term immunobullous is sometimes used. (From Scientific American Medicine, 1990, and Wikipedia)
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
342 |
4. Check minimum number of eventsNone |
342 |
5. Include endpointsNone |
342 |
6. Filter based on genotype QC (FinnGen only) |
342 |
Control definitions (FinnGen only)
- Control exclude
- L12_BULLOUS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF6
- Parent code in ICD-10
- L10-L14
- Name in latin
- Aliae morbositates bullosae
Similar endpoints
↥List of similar endpoints to
Other and unspecified bullous disorders
based on the number of shared cases.
Similar with more cases:
- Other bullous disorders
- Bullous disorders
- Diseases of the skin and subcutaneous tissue
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2861 | 1586 | 1258 |
| Only index persons | 2371 | 1363 | 1008 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.05 | 0.04 |
| Only index persons | 0.05 | 0.05 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 55.73 | 56.47 | 54.87 |
| Only index persons | 56.95 | 56.76 | 57.21 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 342 | 207 | 135 |
| Unadjusted period prevalence (%) | 0.07 | 0.07 | 0.06 |
| Median age at first event (years) | 59.96 | 56.86 | 64.71 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 302
- Matched controls
- 3019
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L13.9
ICD-10 Finland
Bullous disorder, unspecified
10684.7
298.3
236
*
L13.8
ICD-10 Finland
Other specified bullous disorders
665.8
57.6
55
*
L12.0
ICD-10 Finland
Bullous pemphigoid
+∞
49.3
46
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
8.4
38.7
94
154
L30.9
ICD-10 Finland
Dermatitis, unspecified
5.0
28.3
109
309
J04BA02
ATC
dapsone; oral
98.5
25.1
27
*
L13.0
ICD-10 Finland
Dermatitis herpetiformis
271.5
25.1
25
*
TQW80
NOMESCO Finland
Local dermatologic skincare
13.0
23.0
41
36
D07AC01
ATC
betamethasone; topical
3.5
22.6
150
664
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
4.9
21.6
78
199
L12.9
ICD-10 Finland
Pemphigoid, unspecified
+∞
16.8
16
*
D07AD01
ATC
clobetasol; topical
3.7
16.5
81
271
E0000UV
ATC
NA
2.8
15.6
155
835
H02AB06
ATC
prednisolone; systemic
2.7
15.2
176
1034
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
7.2
15.2
37
57
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.6
12.5
124
644
SPAT1148
SPAT
Treatment of chronic ulcer or burn
3.4
12.5
65
224
D07AC13
ATC
mometasone; topical
2.6
12.3
110
539
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
3.9
12.0
51
148
D07AB08
ATC
desonide; topical
4.1
11.8
48
134
A46
ICD-10 Finland
Erysipelas
3.2
10.8
63
232
D07BA04
ATC
hydrocortisone and antiseptics; topical
3.5
10.6
51
164
S97
ICPC
Chronic ulcer skin
5.2
10.4
32
67
XQ802
NOMESCO Finland
Epicutan test
6.2
9.9
26
45
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.3
9.8
52
180
E000001
ATC
NA
2.6
9.8
82
381
D07AB02
ATC
hydrocortisone butyrate; topical
2.4
9.7
105
557
S18
ICPC
Laceration/cut
2.2
9.7
143
874
J01FF01
ATC
clindamycin; systemic
2.4
9.7
103
542
J01DB01
ATC
cefalexin; oral
2.7
9.6
258
2078
R06AE07
ATC
cetirizine; oral
2.1
8.9
148
945
R50.9
ICD-10 Finland
Fever, unspecified
2.8
8.8
60
244
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
3.4
8.7
43
141
R06.0
ICD-10 Finland
Dyspnoea
2.4
8.7
88
446
J05AB11
ATC
valaciclovir; oral
3.0
8.7
53
201
I83.0
ICD-10 Finland
Varicose veins of lower extremities with ulcer
10.5
8.6
16
16
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.6
8.3
68
306
D02AX
ATC
Other emollients and protectives
5.7
8.3
23
43
L30.3
ICD-10 Finland
Infective dermatitis
6.0
8.3
22
39
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
3.3
7.9
39
128
ZX120
NOMESCO Finland
Intravenous
3.1
7.8
44
158
XQ848
NOMESCO Finland
Dermatological photography
5.6
7.5
21
40
J01MA12
ATC
levofloxacin; systemic
2.5
7.5
66
309
L13
ICD-10 Finland
Other bullous disorders
82.0
7.4
8
*
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
2.9
7.4
45
170
S29
ICPC
Skin symptom/complaint other
2.5
7.3
61
279
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.0
7.3
141
930
A02BC02
ATC
pantoprazole; systemic
2.0
7.3
196
1463
C03CA01
ATC
furosemide; systemic
2.1
7.1
97
558
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
2.6
7.1
53
227
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
4.4
7.0
24
58
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
5.1
6.8
20
41
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.0
6.8
39
143
H3600, E103
ICD-10 Finland
NA
17.2
6.8
10
6
L51.9
ICD-10 Finland
Erythema multiforme, unspecified
41.0
6.8
8
*
A10AE05
ATC
insulin detemir; parenteral
4.1
6.8
25
65
H02AB04
ATC
methylprednisolone; systemic
2.4
6.8
57
262
N02BE01
ATC
paracetamol; systemic, rectal
2.3
6.6
261
2219
D05BB02
ATC
acitretin; oral
7.1
6.6
15
22
H04.10
ICD-10 Finland
Dry eye syndrome
2.9
6.5
38
141
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.6
6.5
48
205
A10AB05
ATC
insulin aspart; parenteral (insulins and analog. for injection, fast-acting)
3.3
6.4
31
101
215
Kela drug reimbursment
Diabetes, non-insulin-treated
2.1
6.4
77
418
P01BA02
ATC
hydroxychloroquine; oral
3.1
6.3
35
123
L73.8
ICD-10 Finland
Other specified follicular disorders
27.3
6.3
8
*
QDA99
NOMESCO Finland
Other local destruction of skin of lower limb
27.3
6.3
8
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.8
6.2
40
158
H02AB09
ATC
hydrocortisone; systemic
5.8
6.1
16
29
J01MA02
ATC
ciprofloxacin; systemic
1.9
6.1
124
821
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.0
6.0
93
556
R21
ICD-10 Finland
Rash and other nonspecific skin eruption
4.1
6.0
22
57
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.3
6.0
61
304
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
85
15
75.08
155.02
1.9
1.1
31.2
—
u/ml
—
25
0
72
20
45.33
118.16
1.4
1.2
933.3
—
titre
—
6
0
24
21
12.22
23.37
1.3
1.2
—
—
—
0
0
248
1637
2.87
17.23
14.4
9.1
4.4
4.0
e9/l
1.40
228
1431
213
1354
2.52
15.11
10.2
5.8
26.8
28.6
%
1.16
204
1267
16
16
10.44
14.12
1.1
1.2
—
—
—
0
0
209
1383
2.31
12.61
10.5
6.4
1.2
1.2
mmol/l
1.00
192
1179
184
1189
2.19
11.32
6.8
4.3
34.1
35.7
g/l
3.00
176
1116
62
258
2.71
10.35
5.3
4.0
2.7
1.9
mmol/l
0.77
51
205
167
1092
2.03
9.40
2.2
1.9
95.2
96.1
pmol/l
0.08
95
568
120
702
2.09
9.10
2.2
2.0
3.1
3.1
mg/l
0.00
106
604
270
2131
2.27
8.83
11.7
7.3
82.0
80.6
u/l
0.21
260
1993
128
775
2.04
8.78
4.5
3.1
0.2
0.5
e6/l
1.53
105
579
113
655
2.08
8.72
1.6
1.2
2.5
1.4
u/ml
0.52
32
168
263
2065
2.18
8.54
6.2
4.1
13.5
11.9
mm/h
0.96
255
1895
12
16
7.74
8.46
1.2
2.6
—
—
—
0
0
151
996
1.92
7.91
5.1
3.2
—
—
—
0
0
86
465
2.13
7.87
3.8
2.9
1.2
1.1
e6/l
0.13
61
268
320
2804
3.20
7.09
27.0
13.8
23.5
22.6
mg/l
0.18
268
2229
82
452
2.07
7.07
3.9
2.2
11.4
13.4
umol/l
2.11
77
416
178
1276
1.82
6.88
9.6
5.7
1.2
1.2
mmol/l
1.23
168
1158
80
441
2.06
6.88
4.1
3.1
3.4
2.5
e6/l
0.38
55
245
51
235
2.38
6.80
6.2
6.9
1.5
1.4
mmol/l
0.45
46
224
159
1117
1.79
6.45
2.8
2.3
78.4
76.1
nmol/l
0.48
145
1001
232
1825
1.84
6.40
6.0
4.5
5554.6
2207.5
e6/l
—
5
35
60
304
2.18
6.39
2.0
1.8
—
—
—
0
0
13
26
5.16
6.27
1.2
1.2
—
—
—
0
0
124
815
1.82
6.24
4.2
3.8
12.1
9.5
mg/mmol
0.20
80
490
10
8
12.83
6.12
1.1
1.0
—
—
—
0
0
10
8
12.83
6.12
1.1
1.0
108.0
81.4
%
—
10
8
56
281
2.19
6.10
4.8
3.4
—
—
—
0
0
170
1234
1.75
6.04
3.9
2.6
139.8
119.9
ug/l
0.41
163
1145
43
194
2.39
6.00
1.8
1.5
—
—
—
0
0
280
2361
2.03
5.99
29.9
17.0
14.0
13.7
%
1.87
274
2326
58
298
2.14
5.95
5.8
4.4
242.3
244.1
u/l
0.04
58
286
181
1343
1.74
5.90
5.0
3.7
0.0
0.0
estimate
0.00
28
252
319
2843
2.81
5.82
27.6
15.9
139.1
139.7
mmol/l
3.04
314
2770
97
603
1.85
5.78
2.2
1.9
1.9
1.2
mg/l
0.51
79
467
193
1464
1.73
5.76
8.2
6.1
11.6
12.0
umol/l
0.20
187
1388
59
309
2.10
5.76
2.0
1.9
—
—
—
0
0
183
1371
1.72
5.69
5.0
3.8
0.0
0.0
estimate
0.50
27
240
181
1354
1.72
5.64
7.0
5.0
0.0
0.0
estimate
0.00
29
253
9
7
13.16
5.61
1.0
1.0
—
—
—
0
0
148
1051
1.72
5.55
4.9
3.8
409.5
71.1
ng/l
0.42
108
726
90
561
1.82
5.26
2.1
1.8
420.0
12153957.8
pmol/l
0.50
78
469
318
2855
2.62
5.24
28.2
15.9
3.9
4.0
mmol/l
1.40
313
2778
101
653
1.78
5.22
1.8
1.5
19.5
21.2
nmol/l
0.55
92
551
50
255
2.13
5.22
3.0
2.3
0.2
0.2
g/l
0.19
50
242
36
163
2.35
4.99
2.4
2.8
0.5
0.2
e6/l
0.65
36
158
171
1289
1.65
4.96
4.6
4.1
—
—
—
0
0
20
67
3.11
4.91
1.6
1.2
—
—
—
0
0
66
385
1.89
4.72
4.0
2.3
19.2
23.0
%
1.67
59
339
74
448
1.83
4.71
2.5
1.9
—
—
—
0
0
119
832
1.66
4.54
3.0
2.1
144.4
266.2
u/l
0.85
113
784
60
346
1.89
4.44
27.7
21.4
1.5
1.3
inr
—
7
47
252
2130
1.70
4.41
5.3
3.8
14.8
14.7
pmol/l
0.13
236
1928
321
2942
2.48
4.18
17.8
10.2
25.8
25.4
u/l
0.24
316
2837
42
219
2.05
4.14
2.9
2.7
61.3
63.4
ml/min/173m2
0.13
18
92
8
10
8.16
4.08
2.3
1.0
7.6
9.6
ug/l
—
8
10
204
1654
1.58
4.06
7.1
4.5
7.1
6.6
mmol/l
2.03
197
1530
27
118
2.40
4.06
3.2
2.0
7.3
7.5
g/l
0.17
21
92
27
118
2.40
4.06
3.2
2.0
3.7
3.8
g/l
0.05
21
87
27
118
2.40
4.06
3.2
2.0
—
—
—
0
0
113
799
1.62
4.05
3.9
3.2
1295.9
1330.4
ng/l
0.04
100
680
11
28
4.03
4.01
1.9
1.4
—
—
—
0
0
81
528
1.70
3.96
2.0
1.7
1147.1
1179.8
nmol/l
0.09
67
394
35
173
2.14
3.96
1.7
1.4
—
—
—
0
0
290
2580
1.82
3.86
6.1
4.6
2.0
2.4
mu/l
0.39
277
2347
125
917
1.57
3.79
2.9
3.2
31.2
32.1
u/l
0.11
119
884
7
8
8.90
3.79
1.0
1.0
1708.3
1295.6
miu/ml
—
7
8
73
470
1.70
3.72
1.3
1.3
14.6
30.7
iu/ml
1.77
19
149
127
939
1.56
3.71
4.4
3.2
2.3
2.4
mmol/l
0.33
117
821
40
219
1.94
3.45
2.1
2.7
8.7
5.0
ug/l
0.50
34
194
51
304
1.80
3.39
7.4
6.7
12.2
12.2
kpa
0.02
51
293
51
304
1.80
3.39
7.4
6.7
5.2
5.1
kpa
0.28
51
291
97
687
1.58
3.37
3.8
2.7
8562.0
5633.5
umol/l
0.20
82
582
21
90
2.42
3.31
5.6
2.0
318.5
320.6
ug/l
0.00
21
83
21
90
2.42
3.31
1.3
1.6
—
228.0
—
0
5
15
54
2.86
3.30
2.5
1.3
—
—
—
0
0
17
67
2.62
3.18
2.8
1.5
—
—
—
0
0
287
2586
1.68
3.14
22.7
13.0
80.8
81.5
ml/min/173m2
0.20
246
2126
50
304
1.76
3.11
7.4
6.8
1.3
1.3
mmol/l
0.00
43
241
11
34
3.31
3.08
1.5
1.6
—
—
—
0
0
52
322
1.73
3.04
3.1
2.8
14.3
9.9
umol/l
0.29
45
281
33
179
1.93
2.94
2.8
4.4
1.9
1.7
mmol/l
0.09
22
128
91
654
1.53
2.92
2.6
2.3
—
—
—
0
0
19
83
2.36
2.90
1.3
1.1
—
—
—
0
0
12
41
3.00
2.89
1.8
1.6
—
—
—
0
0
116
880
1.48
2.87
3.9
2.3
51.5
56.1
u/l
0.79
108
814
18
77
2.41
2.87
1.4
1.3
—
—
—
0
0
21
97
2.24
2.83
3.4
2.1
38.9
37.8
g/l
0.39
21
85
14
53
2.71
2.83
1.5
1.5
—
—
—
0
0
75
521
1.56
2.80
2.4
2.8
2.4
2.5
mmol/l
1.88
67
457
281
2547
1.58
2.67
8.2
5.7
41.9
39.8
mmol/mol
2.37
269
2374
75
527
1.54
2.65
5.2
3.6
25.5
232.7
ng/l
2.85
54
403
42
256
1.73
2.61
7.5
7.1
121.4
120.0
g/l
0.17
42
248
31
174
1.86
2.52
7.4
5.9
24.6
24.6
mmol/l
0.01
31
164
16
70
2.35
2.45
1.4
1.3
—
42.1
—
0
7
73
519
1.52
2.44
1.6
1.6
—
—
—
0
0
6
12
5.07
2.41
1.5
1.1
—
—
—
0
0
8
22
3.70
2.38
5.3
3.1
—
—
—
0
0
43
272
1.66
2.34
1.7
2.6
31.9
30.0
u/l
0.12
37
226
12
47
2.61
2.29
1.8
1.6
—
—
—
0
0
8
23
3.54
2.28
1.5
1.4
—
—
—
0
0
6
13
4.68
2.28
1.3
2.4
789.3
1091.2
u/ml
—
6
13
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
15
66
2.33
2.28
3.5
2.3
0.4
0.3
u/ml
—
9
37
211
1844
1.38
2.16
4.1
3.0
58.7
47.3
u/l
1.26
204
1731
10
37
2.75
2.12
1.2
1.4
—
—
—
0
0
13
56
2.37
2.07
1.4
1.4
—
—
—
0
0
13
56
2.37
2.07
1.4
1.4
—
—
—
0
0
130
1059
1.37
2.05
5.4
3.8
—
—
—
0
0
15
71
2.16
1.95
1.1
1.2
—
—
—
0
0
288
2674
1.49
1.94
5.3
4.5
6.1
5.9
mmol/l
1.63
279
2444
10
39
2.61
1.94
1.5
1.6
—
—
—
0
0
17
85
2.05
1.94
2.0
2.4
1452.0
2721.3
u/l
—
5
31
295
2753
1.52
1.93
5.4
4.9
2.6
2.7
mmol/l
1.65
277
2537
27
160
1.75
1.88
2.2
3.5
4.2
4.6
pmol/l
1.04
21
141
8
28
2.90
1.87
1.0
1.0
—
—
—
0
0
290
2704
1.48
1.83
4.9
4.4
4.5
4.7
mmol/l
1.95
273
2505
63
462
1.45
1.81
1.3
1.3
1.6
10.3
u/ml
2.81
17
183
47
325
1.52
1.80
13.1
7.5
—
—
—
0
0
17
88
1.98
1.78
1.9
1.2
—
—
—
0
0
274
2534
1.41
1.76
26.4
14.9
38.6
40.0
%
1.75
194
1874
80
619
1.38
1.70
5.2
3.9
1.0
1.0
kg/l
0.16
14
88
12
55
2.22
1.69
1.4
1.3
224.0
221.0
u/ml
—
6
26
45
313
1.50
1.68
1.6
1.8
1.4
1.4
%
0.03
39
276
14
69
2.07
1.67
1.7
1.2
—
—
—
0
0
5
14
3.61
1.62
1.6
5.3
104.2
87.3
%
—
5
14
14
70
2.04
1.61
2.9
1.7
—
—
—
0
0
12
57
2.15
1.57
1.4
1.2
—
—
—
0
0
14
71
2.01
1.56
2.9
1.7
—
—
—
0
0
16
86
1.90
1.53
1.6
1.5
—
—
—
0
0
9
37
2.47
1.49
2.1
1.5
—
—
—
0
0
286
2686
1.40
1.48
4.7
4.4
1.4
1.5
mmol/l
2.27
267
2470
7
28
2.53
1.46
7.7
2.3
—
—
—
0
0
5
16
3.16
1.44
3.2
1.4
—
—
—
0
0
5
16
3.16
1.44
3.2
1.4
—
—
—
0
0
277
2593
1.36
1.42
4.5
4.0
1.4
1.3
mmol/l
1.55
260
2376
7
29
2.44
1.40
1.0
1.1
—
—
—
0
0
6
23
2.64
1.37
1.2
1.0
—
—
—
0
0
6
24
2.53
1.31
1.0
1.2
—
—
—
0
0
5
18
2.80
1.29
3.2
1.4
—
—
—
0
0
5
18
2.80
1.29
3.2
1.4
—
—
—
0
0
5
18
2.80
1.29
1.0
1.1
—
—
—
0
0
11
55
2.03
1.28
1.2
1.9
—
—
—
0
0
15
85
1.80
1.25
1.3
1.2
—
—
—
0
0
90
744
1.28
1.21
5.1
4.0
0.0
0.0
estimate
0.00
26
249
6
26
2.33
1.19
1.8
1.8
—
—
—
0
0
15
87
1.76
1.17
1.3
1.2
—
—
—
0
0
17
104
1.67
1.11
1.6
2.0
—
—
—
0
0
29
203
1.47
1.09
8.3
3.7
168.4
75.1
ng/l
1.34
23
180
10
53
1.91
1.02
3.1
1.8
—
—
—
0
0
7
36
1.96
0.97
3.9
2.0
—
—
—
0
0
13
78
1.69
0.93
13.2
4.1
—
3.2
—
0
8
6
28
2.16
0.92
1.0
1.1
—
—
—
0
0
6
30
2.02
0.87
4.3
1.9
—
—
—
0
0
6
30
2.02
0.87
4.3
1.9
—
—
—
0
0
6
30
2.02
0.87
4.3
1.9
—
—
—
0
0
6
31
1.95
0.85
1.2
1.6
—
—
—
0
0
8
46
1.76
0.83
1.0
1.1
—
—
—
0
0
19
131
1.48
0.80
10.9
9.6
24.6
24.7
mmol/l
0.04
19
122
6
33
1.83
0.79
4.3
2.1
—
—
—
0
0
85
733
1.21
0.79
1.9
1.6
1.4
1.4
mmol/l
0.37
75
623
19
134
1.44
0.73
1.3
1.9
—
—
—
0
0
5
25
2.01
0.73
1.0
1.3
—
—
—
0
0
23
169
1.39
0.71
1.5
2.0
—
—
—
0
0
7
41
1.72
0.70
1.4
1.6
—
—
—
0
0
10
61
1.66
0.69
1.3
1.5
—
—
—
0
0
5
27
1.86
0.68
1.4
1.5
—
—
—
0
0
191
1786
1.16
0.66
3.1
3.1
—
—
—
0
0
22
167
1.34
0.58
2.3
1.7
—
—
—
0
0
6
35
1.73
0.58
1.0
1.1
—
—
—
0
0
6
37
1.63
0.56
1.0
1.1
—
—
—
0
0
6
38
1.59
0.54
3.2
3.1
10.8
10.7
umol/l
—
6
26
9
63
1.44
0.52
3.7
1.9
—
—
—
0
0
12
83
1.46
0.52
2.1
1.4
—
—
—
0
0
12
84
1.44
0.50
1.2
1.4
—
265.3
—
0
37
7
46
1.53
0.48
1.0
1.3
—
—
—
0
0
37
312
1.21
0.45
2.1
2.1
—
—
—
0
0
7
50
1.41
0.45
1.1
1.6
162.3
215.7
pmol/l
—
7
44
12
86
1.41
0.45
3.2
2.4
—
—
—
0
0
11
78
1.42
0.43
1.0
1.8
—
—
—
0
0
8
56
1.44
0.43
5.3
3.0
17.0
32.2
u/ml
—
8
56
9
66
1.37
0.38
1.2
1.3
3.7
3.9
mmol/l
—
9
60
9
68
1.33
0.38
1.3
1.3
—
—
—
0
0
9
71
1.27
0.36
2.1
1.5
—
—
—
0
0
6
47
1.28
0.32
1.2
1.1
—
—
—
0
0
11
83
1.34
0.32
1.4
1.4
—
—
—
0
0
8
65
1.24
0.27
2.1
1.4
—
—
—
0
0
8
65
1.24
0.27
2.1
1.4
—
—
—
0
0
8
65
1.24
0.27
2.1
1.4
—
—
—
0
0
14
114
1.24
0.25
4.0
2.0
—
—
—
0
0
32
284
1.14
0.24
1.8
1.9
—
—
—
0
0
5
38
1.32
0.23
1.0
1.1
—
—
—
0
0
19
163
1.18
0.22
5.4
2.8
40.0
53.0
u/ml
0.19
19
157
13
107
1.22
0.22
2.8
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
2.0
—
124.0
—
0
11
82
774
1.08
0.21
4.5
5.2
1.7
2.9
ug/l
1.57
76
691
5
43
1.17
0.21
1.0
1.1
—
4.4
u/ml
—
0
22
65
613
1.07
0.17
4.8
4.5
23.5
21.4
%
0.47
28
292
11
128
0.85
0.14
1.9
1.5
—
—
—
0
0
17
154
1.11
0.10
1.3
1.3
—
—
—
0
0
6
54
1.11
0.09
1.0
1.1
—
—
—
0
0
46
441
1.05
0.08
2.6
3.1
0.8
0.8
ug/l
0.06
35
286
6
73
0.82
0.07
1.5
1.3
—
—
—
0
0
18
191
0.94
0.05
1.2
1.2
29.2
129.4
iu/ml
—
7
78
31
298
1.04
0.04
3.5
4.1
16.0
36.0
ug/l
0.34
24
251
23
239
0.96
0.03
1.2
1.7
—
—
—
0
0
10
101
0.99
0.00
1.4
1.6
—
—
—
0
0
45
447
1.01
0.00
1.9
1.4
—
—
—
0
0
15
154
0.97
0.00
1.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
2.7
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_OTHERBULL and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_OTHERBULL | 1.902 [1.48, 2.45] | < 0.001 |
| Birth year | 0.992 [0.98, 1.0] | 0.074 |
During the follow-up period (1.1.1998 — 31.12.2019), 276 out of 1248 females with L12_OTHERBULL died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_OTHERBULL | 2.2 [1.6, 3.02] | < 0.001 |
| Birth year | 0.984 [0.97, 0.99] | 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 245 out of 961 males with L12_OTHERBULL died.
Mortality risk
Mortality risk for people of age
years, who have L12_OTHERBULL.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.175% | 0.288% |
| 5 | 1.006% | 2.259% |
| 10 | 2.608% | 6.262% |
| 15 | 4.971% | 11.153% |
| 20 | 8.711% | 18.21% |
Relationships between endpoints
↥Index endpoint: L12_OTHERBULL – Other and unspecified bullous disorders
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data